163 related articles for article (PubMed ID: 18671911)
1. Oxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy.
Ortenzi A; Paggi A; Foschi N; Sabbatini D; Pistoli E
Funct Neurol; 2008; 23(2):97-100. PubMed ID: 18671911
[TBL] [Abstract][Full Text] [Related]
2. Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy.
Sattler A; Schaefer M; May TW
Seizure; 2015 Sep; 31():149-54. PubMed ID: 26362393
[TBL] [Abstract][Full Text] [Related]
3. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy.
Striano S; Striano P; Di Nocera P; Italiano D; Fasiello C; Ruosi P; Bilo L; Pisani F
Epilepsy Res; 2006 May; 69(2):170-6. PubMed ID: 16515857
[TBL] [Abstract][Full Text] [Related]
4. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children.
Holtmann M; Krause M; Opp J; Tokarzewski M; Korn-Merker E; Boenigk HE
Neuropediatrics; 2002 Dec; 33(6):298-300. PubMed ID: 12571784
[TBL] [Abstract][Full Text] [Related]
5. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy.
Lin CH; Lu CH; Wang FJ; Tsai MH; Chang WN; Tsai NW; Lai SL; Tseng YL; Chuang YC
Clin Neuropharmacol; 2010; 33(6):293-6. PubMed ID: 20881597
[TBL] [Abstract][Full Text] [Related]
6. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy.
Park KJ; Kim JR; Joo EY; Seo DW; Hong SB; Ko JW; Kim SR; Huh W; Lee SY
Clin Neuropharmacol; 2012; 35(1):40-4. PubMed ID: 22246398
[TBL] [Abstract][Full Text] [Related]
7. Hyponatremia from oxcarbazepine and carbamazepine.
Dong X; Leppik IE; White J; Rarick J
Neurology; 2005 Dec; 65(12):1976-8. PubMed ID: 16380624
[TBL] [Abstract][Full Text] [Related]
8. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
9. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy.
Berghuis B; van der Palen J; de Haan GJ; Lindhout D; Koeleman BPC; Sander JW;
Epilepsia; 2017 Jul; 58(7):1227-1233. PubMed ID: 28542738
[TBL] [Abstract][Full Text] [Related]
10. Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia.
Kim YS; Kim DW; Jung KH; Lee ST; Kang BS; Byun JI; Yeom JS; Chu K; Lee SK
Seizure; 2014 Mar; 23(3):208-12. PubMed ID: 24378204
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
[TBL] [Abstract][Full Text] [Related]
12. Conversion from carbamazepine or oxcarbazepine to topiramate in adolescents and adults with epilepsy.
Kowalik A; Rimpau W; Adam H; Kühn F; van Oene J; Schreiner A; Bogdanow M; Schauble B;
Acta Neurol Scand; 2008 Mar; 117(3):159-66. PubMed ID: 18218062
[TBL] [Abstract][Full Text] [Related]
13. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L
Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine.
Mintzer S; Boppana P; Toguri J; DeSantis A
Epilepsia; 2006 Mar; 47(3):510-5. PubMed ID: 16529614
[TBL] [Abstract][Full Text] [Related]
15. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?
Schmidt D; Elger CE
Epilepsy Behav; 2004 Oct; 5(5):627-35. PubMed ID: 15380112
[TBL] [Abstract][Full Text] [Related]
16. [Oxcarbazepine in the treatment of epilepsy. A review and update].
Horga de la Parte JF; Horga A
Rev Neurol; 2006 Jan 16-31; 42(2):95-113. PubMed ID: 16450324
[TBL] [Abstract][Full Text] [Related]
17. Symptomatology of carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy.
Berghuis B; Hulst J; Sonsma A; McCormack M; de Haan GJ; Sander JW; Lindhout D; Koeleman BPC
Epilepsia; 2021 Mar; 62(3):778-784. PubMed ID: 33576502
[TBL] [Abstract][Full Text] [Related]
18. Hyponatremic coma under oxcarbazepine therapy.
Steinhoff BJ; Stoll KD; Stodieck SR; Paulus W
Epilepsy Res; 1992 Mar; 11(1):67-70. PubMed ID: 1563340
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy.
Kim DW; Gu N; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Kim HS; Oh J; Lee SK
Epilepsia; 2012 Jan; 53(1):e9-12. PubMed ID: 22091603
[TBL] [Abstract][Full Text] [Related]
20. Short-term impact of the switch from immediate-release to extended-release oxcarbazepine in epilepsy patients on high dosages.
Steinhoff BJ; Wendling AS
Epilepsy Res; 2009 Dec; 87(2-3):256-9. PubMed ID: 19850448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
